Designed trimer-mimetic TNF superfamily ligands on self-assembling nanocages

Minwoo Kih, Eun Jung Lee, Na Kyeong Lee, Yoon Kyoung Kim, Kyung Eun Lee, Cherlhyun Jeong, Yoosoo Yang, Dong-Hwee Kim, In-San Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Presentation of an endogenous bioactive ligand in its native form is a key factor in controlling and determining its bioactivity, stability, and therapeutic efficacy. In this study, we developed a novel strategy for presenting trimeric ligands on nanocages by designing, optimizing and testing based on the rational design, high-resolution structural analysis and agonistic activity assays in vitro and in vivo. We successfully designed a nanocage that presents the TNF superfamily member, TRAIL (TNF-related apoptosis-inducing ligand) in its native-like trimeric structure. The native structure of TRAIL complexes was mimicked on the resulting trimeric TRAIL-presenting nanocages (TTPNs) by inserting sufficient spacing, determined from three-dimensional structural models, to provide optimal access to the corresponding receptors. The efficacy of TTPNs as an anti-tumor agent was confirmed in preclinical studies, which revealed up to 330-fold increased affinity, 62.5-fold enhanced apoptotic activity, and improved pharmacokinetic characteristics and stability compared with the monomeric form of TRAIL (mTRAIL). In this latter context, TTPNs exhibited greater than 90% stability over 1 mo, whereas ∼50% of mTRAIL aggregated within 2 d. Consistent with their enhanced stability and ultra-high affinity for the TRAIL receptor, TTPNs effectively induced apoptosis of tumor cells in vivo, leading to effective inhibition of tumor growth. Although TRAIL was used here as a proof-of-concept, all members of the TNF superfamily share the TNF homology domain (THD) and have similar distances between ecto-domain C-termini. Thus, other TNF superfamily ligands could be genetically substituted for the TRAIL ligand on the surface of this biomimetic delivery platform.

Original languageEnglish
Pages (from-to)67-77
Number of pages11
JournalBiomaterials
Volume180
DOIs
Publication statusPublished - 2018 Oct 1

Fingerprint

TNF-Related Apoptosis-Inducing Ligand
Cell death
Ligands
Tumors
TNF-Related Apoptosis-Inducing Ligand Receptors
Neoplasms
Biomimetics
Pharmacokinetics
Structural Models
Bioactivity
Structural analysis
Assays
Cells
Apoptosis
Testing
Growth

Keywords

  • Biomimetic delivery platform
  • Nanocages
  • Stability
  • Trimeric structure
  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Designed trimer-mimetic TNF superfamily ligands on self-assembling nanocages. / Kih, Minwoo; Lee, Eun Jung; Lee, Na Kyeong; Kim, Yoon Kyoung; Lee, Kyung Eun; Jeong, Cherlhyun; Yang, Yoosoo; Kim, Dong-Hwee; Kim, In-San.

In: Biomaterials, Vol. 180, 01.10.2018, p. 67-77.

Research output: Contribution to journalArticle

Kih, Minwoo ; Lee, Eun Jung ; Lee, Na Kyeong ; Kim, Yoon Kyoung ; Lee, Kyung Eun ; Jeong, Cherlhyun ; Yang, Yoosoo ; Kim, Dong-Hwee ; Kim, In-San. / Designed trimer-mimetic TNF superfamily ligands on self-assembling nanocages. In: Biomaterials. 2018 ; Vol. 180. pp. 67-77.
@article{5a919bae4e09488fb807edb8bc920a69,
title = "Designed trimer-mimetic TNF superfamily ligands on self-assembling nanocages",
abstract = "Presentation of an endogenous bioactive ligand in its native form is a key factor in controlling and determining its bioactivity, stability, and therapeutic efficacy. In this study, we developed a novel strategy for presenting trimeric ligands on nanocages by designing, optimizing and testing based on the rational design, high-resolution structural analysis and agonistic activity assays in vitro and in vivo. We successfully designed a nanocage that presents the TNF superfamily member, TRAIL (TNF-related apoptosis-inducing ligand) in its native-like trimeric structure. The native structure of TRAIL complexes was mimicked on the resulting trimeric TRAIL-presenting nanocages (TTPNs) by inserting sufficient spacing, determined from three-dimensional structural models, to provide optimal access to the corresponding receptors. The efficacy of TTPNs as an anti-tumor agent was confirmed in preclinical studies, which revealed up to 330-fold increased affinity, 62.5-fold enhanced apoptotic activity, and improved pharmacokinetic characteristics and stability compared with the monomeric form of TRAIL (mTRAIL). In this latter context, TTPNs exhibited greater than 90{\%} stability over 1 mo, whereas ∼50{\%} of mTRAIL aggregated within 2 d. Consistent with their enhanced stability and ultra-high affinity for the TRAIL receptor, TTPNs effectively induced apoptosis of tumor cells in vivo, leading to effective inhibition of tumor growth. Although TRAIL was used here as a proof-of-concept, all members of the TNF superfamily share the TNF homology domain (THD) and have similar distances between ecto-domain C-termini. Thus, other TNF superfamily ligands could be genetically substituted for the TRAIL ligand on the surface of this biomimetic delivery platform.",
keywords = "Biomimetic delivery platform, Nanocages, Stability, Trimeric structure, Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)",
author = "Minwoo Kih and Lee, {Eun Jung} and Lee, {Na Kyeong} and Kim, {Yoon Kyoung} and Lee, {Kyung Eun} and Cherlhyun Jeong and Yoosoo Yang and Dong-Hwee Kim and In-San Kim",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.biomaterials.2018.07.009",
language = "English",
volume = "180",
pages = "67--77",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Designed trimer-mimetic TNF superfamily ligands on self-assembling nanocages

AU - Kih, Minwoo

AU - Lee, Eun Jung

AU - Lee, Na Kyeong

AU - Kim, Yoon Kyoung

AU - Lee, Kyung Eun

AU - Jeong, Cherlhyun

AU - Yang, Yoosoo

AU - Kim, Dong-Hwee

AU - Kim, In-San

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Presentation of an endogenous bioactive ligand in its native form is a key factor in controlling and determining its bioactivity, stability, and therapeutic efficacy. In this study, we developed a novel strategy for presenting trimeric ligands on nanocages by designing, optimizing and testing based on the rational design, high-resolution structural analysis and agonistic activity assays in vitro and in vivo. We successfully designed a nanocage that presents the TNF superfamily member, TRAIL (TNF-related apoptosis-inducing ligand) in its native-like trimeric structure. The native structure of TRAIL complexes was mimicked on the resulting trimeric TRAIL-presenting nanocages (TTPNs) by inserting sufficient spacing, determined from three-dimensional structural models, to provide optimal access to the corresponding receptors. The efficacy of TTPNs as an anti-tumor agent was confirmed in preclinical studies, which revealed up to 330-fold increased affinity, 62.5-fold enhanced apoptotic activity, and improved pharmacokinetic characteristics and stability compared with the monomeric form of TRAIL (mTRAIL). In this latter context, TTPNs exhibited greater than 90% stability over 1 mo, whereas ∼50% of mTRAIL aggregated within 2 d. Consistent with their enhanced stability and ultra-high affinity for the TRAIL receptor, TTPNs effectively induced apoptosis of tumor cells in vivo, leading to effective inhibition of tumor growth. Although TRAIL was used here as a proof-of-concept, all members of the TNF superfamily share the TNF homology domain (THD) and have similar distances between ecto-domain C-termini. Thus, other TNF superfamily ligands could be genetically substituted for the TRAIL ligand on the surface of this biomimetic delivery platform.

AB - Presentation of an endogenous bioactive ligand in its native form is a key factor in controlling and determining its bioactivity, stability, and therapeutic efficacy. In this study, we developed a novel strategy for presenting trimeric ligands on nanocages by designing, optimizing and testing based on the rational design, high-resolution structural analysis and agonistic activity assays in vitro and in vivo. We successfully designed a nanocage that presents the TNF superfamily member, TRAIL (TNF-related apoptosis-inducing ligand) in its native-like trimeric structure. The native structure of TRAIL complexes was mimicked on the resulting trimeric TRAIL-presenting nanocages (TTPNs) by inserting sufficient spacing, determined from three-dimensional structural models, to provide optimal access to the corresponding receptors. The efficacy of TTPNs as an anti-tumor agent was confirmed in preclinical studies, which revealed up to 330-fold increased affinity, 62.5-fold enhanced apoptotic activity, and improved pharmacokinetic characteristics and stability compared with the monomeric form of TRAIL (mTRAIL). In this latter context, TTPNs exhibited greater than 90% stability over 1 mo, whereas ∼50% of mTRAIL aggregated within 2 d. Consistent with their enhanced stability and ultra-high affinity for the TRAIL receptor, TTPNs effectively induced apoptosis of tumor cells in vivo, leading to effective inhibition of tumor growth. Although TRAIL was used here as a proof-of-concept, all members of the TNF superfamily share the TNF homology domain (THD) and have similar distances between ecto-domain C-termini. Thus, other TNF superfamily ligands could be genetically substituted for the TRAIL ligand on the surface of this biomimetic delivery platform.

KW - Biomimetic delivery platform

KW - Nanocages

KW - Stability

KW - Trimeric structure

KW - Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

UR - http://www.scopus.com/inward/record.url?scp=85053184687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053184687&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2018.07.009

DO - 10.1016/j.biomaterials.2018.07.009

M3 - Article

C2 - 30025246

AN - SCOPUS:85053184687

VL - 180

SP - 67

EP - 77

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -